Infection Risk With Biologic Therapy in Patients With Inflammatory Bowel Disease

被引：30

作者：

Hindryckx, Pieter ^{[1
]}

Novak, Gregor ^{[2
]}

Bonovas, Stefanos ^{[3
]}

Peyrin-Biroulet, Laurent ^{[4
]}

Danese, Silvio ^{[3
,5
]}

机构：

[1] Univ Ghent, Dept Gastroenterol, Ghent, Belgium

[2] Univ Ljubljana, Dept Gastroenterol, Med Ctr, Ljubljana, Slovenia

[3] Humanitas Clin & Res Ctr, IBD Ctr, Dept Gastroenterol, Milan, Italy

[4] Lorraine Univ, Univ Hosp Nancy, Inserm, U954, Vandoeuvre Les Nancy, France

[5] Humanitas Univ, Dept Biomed Sci, Milan, Italy

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2017年 / 102卷 / 04期

关键词：

NONSTEROIDAL ANTIINFLAMMATORY DRUGS; EVENT TRIAL TARGET; CARDIOVASCULAR SAFETY; CENTRAL SENSITIZATION; CHRONIC PAIN; CYCLOOXYGENASE ISOFORMS; OSTEOARTHRITIS PAIN; ARTHRITIS RESEARCH; KNEE REPLACEMENT; COX-2; INHIBITION;

D O I：

10.1002/cpt.791

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The development of biologic drugs revolutionized the management of inflammatory bowel diseases: Crohn's disease and ulcerative colitis. However, while their efficacy has been well established, it remains uncertain to what extent biologic treatments may be associated with important safety risks, such as serious infections, opportunistic infections, or tuberculosis reactivation. Herein, we review and discuss the current evidence on the infection risk associated with biologic therapy in patients with inflammatory bowel disease (IBD).

引用

页码：633 / 641

页数：9

共 101 条

[1] CLINICAL TRIAL OF ADJUNCTIVE CELECOXIB TREATMENT IN PATIENTS WITH MAJOR DEPRESSION: A DOUBLE BLIND AND PLACEBO CONTROLLED TRIAL [J].